NCT03549494 is a Phase 2 clinical trial of Ocoxin-Viusid® in Stomach Neoplasm, sponsored by Catalysis SL.

Who is sponsoring NCT03549494?

NCT03549494 is sponsored by Catalysis SL.

What drugs are being tested in NCT03549494?

Interventions in NCT03549494: Ocoxin-Viusid®.

What condition does NCT03549494 study?

NCT03549494 studies Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms, Head and Neck Neoplasms, Gastrointestinal Disease, Digestive System Disease, Esophageal Diseases, Stomach Diseases, Esophagogastric Junction Disorder.

Is NCT03549494 still recruiting?

NCT03549494 is currently completed. Last updated 7 February 2024.

Last reviewed 2024-02-07 · How we verify

NCT03549494

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction

Completed Phase 2 Last updated 7 February 2024

What this trial tests

Phase 2 trial testing Ocoxin-Viusid® in Stomach Neoplasm in 45 participants. Completed in 15 February 2023.

Timeline

25 October 2018

Primary endpoint
15 June 2022

15 February 2023

Quick facts

Lead sponsor	Catalysis SL
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	45
Start date	25 October 2018
Primary completion	15 June 2022
Estimated completion	15 February 2023
Sites	1 location across Cuba

Drugs / interventions tested

Ocoxin-Viusid®

Conditions studied

Stomach Neoplasm — all drugs for Stomach Neoplasm →
Gastrointestinal Neoplasms — all drugs for Gastrointestinal Neoplasms →
Digestive System Neoplasm — all drugs for Digestive System Neoplasm →
Esophageal Neoplasms — all drugs for Esophageal Neoplasms →

Sponsor

Catalysis SL — full company profile →

Who can join

18 and older, any sex, with Stomach Neoplasm or Gastrointestinal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our main objective is to evaluate the effect of Ocoxin-Viusid on the quality of life of patients with advanced stomach cancer and esophagogastric junction. The Ocoxin-Viusid nutritional supplement is expected to improve quality of life and tolerance to treatment with Chemotherapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ocoxin-Viusid®

Trials testing the same drug.

NCT03717298 — Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma · Phase 2 · completed

Other recruiting trials for Stomach Neoplasm

Currently open trials in the same condition.

NCT06732856 — A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locall · Phase 1, PHASE2 · recruiting
NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
NCT06923449 — Gastric Cancer' Textbook Oncological Outcome and Tumor Board Performance · recruiting
NCT05180864 — Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer · NA · recruiting
NCT05640609 — Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer · Phase 1, PHASE2 · recruiting

Other Catalysis SL trials

Trials by the same sponsor.

NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03549494 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
Last refreshed: 7 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03549494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing